Eli Lilly And Co (NYSE:LLY) updated its FY20 earnings guidance on Thursday. The company provided EPS guidance of $7.20-$7.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.84. The company issued revenue guidance of $23.7-$24.2 billion, compared to the consensus revenue estimate of $23.94 billion.Eli Lilly And Co also updated its FY 2020
Pre-Market guidance to 7.20-7.40 EPS.

Several research firms have issued reports on LLY. Cowen upped their target price on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the company an outperform rating in a research note on Wednesday, April 15th. ValuEngine cut shares of Eli Lilly And Co from a hold rating to a sell rating in a research note on Saturday. UBS Group cut shares of Eli Lilly And Co from a buy rating to a neutral rating and increased their price objective for the stock from $157.00 to $158.00 in a research note on Monday, April 20th. Bank of America reiterated a buy rating and issued a $180.00 price objective on shares of Eli Lilly And Co in a research note on Friday, June 19th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly And Co from $175.00 to $190.00 and gave the stock an overweight rating in a research note on Wednesday, June 17th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $168.58.

Eli Lilly And Co stock opened at $150.29 on Friday. The firm has a 50 day moving average of $160.88 and a 200 day moving average of $148.62. The firm has a market capitalization of $143.74 billion, a price-to-earnings ratio of 21.94, a P/E/G ratio of 1.32 and a beta of 0.26. Eli Lilly And Co has a 12-month low of $101.36 and a 12-month high of $170.75. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 4.37.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Thursday, July 30th. The company reported $1.89 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.58 by $0.31. Eli Lilly And Co had a net margin of 24.48% and a return on equity of 200.78%. The company had revenue of $5.50 billion during the quarter, compared to analyst estimates of $5.77 billion. During the same period in the prior year, the firm posted $1.50 EPS. The firm’s quarterly revenue was down 2.4% compared to the same quarter last year. On average, analysts predict that Eli Lilly And Co will post 7.3 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date is Thursday, August 13th. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 49.01%.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 11,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $170.00, for a total transaction of $1,870,000.00. Following the completion of the sale, the senior vice president now directly owns 18,646 shares of the company’s stock, valued at approximately $3,169,820. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 12,961 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $169.69, for a total transaction of $2,199,352.09. Following the sale, the insider now directly owns 111,132,563 shares of the company’s stock, valued at $18,858,084,615.47. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 555,236 shares of company stock valued at $91,393,391. Insiders own 0.09% of the company’s stock.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Dow Jones Industrial Average (DJIA)

Earnings History and Estimates for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.